NASDAQ: BMGLBasel Medical Group Ltd Stock
$4.18+0.01 (+0.24%)
Updated Apr 29, 2025
BMGL Price
$4.18
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$3.63
52 Week High
$5.50
P/E
46.44x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$7.42M
Earnings
$1.53M
Gross Margin
77.6%
Operating Margin
25.68%
Profit Margin
20.6%
Debt to Equity
1.16
Operating Cash Flow
$2M
Beta
0.56
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BMGL Overview
Basel Medical Group Ltd provides healthcare services. The company offers services in the areas of medical specialists, medical supplies and equipment, medical technology, and pharmaceuticals. The company was incorporated in 2023 and is based in Singapore.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BMGL's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
A
BMGL
Ranked#21 of 42
Ranked#21 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.56 | A | |
| $12.65 | A | |
| $14.03 | A |
Be the first to know about important BMGL news, forecast changes, insider trades & much more!
BMGL News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BMGL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BMGL was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BMGL is poor value based on its earnings relative to its share price (46.44x), compared to the US market average (29.19x)
P/E vs Market Valuation
BMGL is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more BMGL due diligence checks available for Premium users.
Valuation
BMGL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
46.44x
Industry
14.71x
Market
29.19x
BMGL is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BMGL is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
BMGL's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
BMGL's Earnings (EBIT) of $1.90M... subscribe to Premium to read more.
Interest Coverage Financials
BMGL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$12.0M
Liabilities
$6.5M
Debt to equity
1.16
BMGL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
BMGL's operating cash flow ($1.85M)... subscribe to Premium to read more.
Debt Coverage Financials
Basel Medical Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.